Bulletin
Investor Alert

New York Markets Open in:

Dec. 22, 2015, 11:41 a.m. EST

PSivida shares skyrocket after drug meets trial goals

Stock hits 5-year high on volume of more than 100 times the full-day average

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

By Emma Court


PSivida Corp.
A tiny Medidur insert could cause a big move in pSivida’s stock

NEW YORK (MarketWatch) -- PSivida Corp.’s stock soared on heavy volume Tuesday, after the company reported positive results from a late-stage clinical trial for a new eye disease-treating drug.

Shares of pSivida  ran up as much as 57% in morning trade to an intraday high of $5.81, the highest price seen since December 2010, before paring some gains. Volume in the first two hours of trade was about 9.7 million shares, or more than 100 times the full-day average of 84,140 shares, according to FactSet.

The company said early Tuesday that Medidur, a drug that treats chronic noninfectious posterior uveitis, met its primary efficacy endpoint in a Phase 3 trial. Of the 129 patients at multiple centers that participated in the trial, 18.4% of those treated with Medidur saw posterior uveitis recur at the six month follow-up, compared to 78.6% of control eyes.

The finding was “highly statistically significant,” the company said in a statement. The trial’s principal investigator, Dr. Glenn Jaffe of Duke University, called the results “extraordinary.”

“With a single injection, Medidur showed the ability to control the recurrence of posterior uveitis, improve visual acuity and prevent vision loss,” Jaffe said.

Uveitis is an eye inflammation that can cause temporary and permanent vision problems in one or both eyes. It is found most in adults ages 20 to 50. Posterior uveitis is a rarer form of the group of diseases and estimated to affect 75,000 people in the US.

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.